ATE270553T1 - Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren - Google Patents

Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren

Info

Publication number
ATE270553T1
ATE270553T1 AT99118533T AT99118533T ATE270553T1 AT E270553 T1 ATE270553 T1 AT E270553T1 AT 99118533 T AT99118533 T AT 99118533T AT 99118533 T AT99118533 T AT 99118533T AT E270553 T1 ATE270553 T1 AT E270553T1
Authority
AT
Austria
Prior art keywords
tumors
treatment
administering
production
medicinal product
Prior art date
Application number
AT99118533T
Other languages
English (en)
Inventor
Martin Brown
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE270553T1 publication Critical patent/ATE270553T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99118533T 1993-09-22 1994-09-19 Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren ATE270553T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/125,609 US5484612A (en) 1993-09-22 1993-09-22 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin

Publications (1)

Publication Number Publication Date
ATE270553T1 true ATE270553T1 (de) 2004-07-15

Family

ID=22420569

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94202693T ATE193827T1 (de) 1993-09-22 1994-09-19 Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
AT99118533T ATE270553T1 (de) 1993-09-22 1994-09-19 Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94202693T ATE193827T1 (de) 1993-09-22 1994-09-19 Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren

Country Status (22)

Country Link
US (4) US5484612A (de)
EP (2) EP0649658B1 (de)
JP (1) JPH07215882A (de)
KR (1) KR100383402B1 (de)
AT (2) ATE193827T1 (de)
AU (1) AU690132B2 (de)
CA (1) CA2132578C (de)
CZ (1) CZ289742B6 (de)
DE (2) DE69433889T2 (de)
DK (2) DK0972517T3 (de)
ES (2) ES2147567T3 (de)
GR (1) GR3034360T3 (de)
HU (1) HUT71119A (de)
IL (1) IL111025A (de)
MY (1) MY112405A (de)
NO (1) NO943524L (de)
NZ (2) NZ264502A (de)
PT (2) PT649658E (de)
RU (1) RU2148406C1 (de)
SG (1) SG52568A1 (de)
SK (1) SK282178B6 (de)
UA (1) UA49787C2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
EP1014990B1 (de) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
AU1585799A (en) * 1997-11-14 1999-06-07 General Hospital Corporation, The Treatment of hematologic disorders
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6819761B1 (en) * 1999-09-16 2004-11-16 Silicon Laboratories, Inc. Programmable constant current “off hook” circuit
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ATE408606T1 (de) 1999-12-21 2008-10-15 Ufz Leipzighalle Gmbh Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
RU2192862C1 (ru) * 2001-05-23 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения больших и мультицентричных ретинобластом
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
RU2234916C2 (ru) * 2002-10-29 2004-08-27 Московский областной научно-исследовательский клинический институт Способ лечения онкологических больных
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
RU2243766C1 (ru) * 2003-04-01 2005-01-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидивов рака шейки матки
EP1723125A4 (de) * 2004-03-01 2009-11-18 Auckland Uniservices Ltd Neue 1,2,4-benzotriazin-1,4-dioxide
ATE491695T1 (de) * 2005-03-31 2011-01-15 Auckland Uniservices Ltd Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen
CA2624707A1 (en) * 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
EP2244760B8 (de) * 2008-01-28 2022-07-20 Implantica Patent Ltd. Implantierbare drainagevorrichtung
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US9316632B2 (en) * 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de) 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
WO2013086467A1 (en) * 2011-12-07 2013-06-13 Sri International Benzotriazine oxides as drugs targeting mycobacterium tuberculosis
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
JP7682097B2 (ja) 2019-03-27 2025-05-23 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
TWI877182B (zh) * 2019-07-01 2025-03-21 美商古拉森療法公司 β腎上腺素激動劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US4923878A (en) * 1988-11-14 1990-05-08 Merck & Co., Inc. Quinolizine sulfonamides used against certain neoplastic disease states
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Also Published As

Publication number Publication date
CZ232694A3 (en) 1995-09-13
KR950007853A (ko) 1995-04-15
PT649658E (pt) 2000-12-29
JPH07215882A (ja) 1995-08-15
IL111025A (en) 2006-04-10
US5670502A (en) 1997-09-23
US6277835B1 (en) 2001-08-21
DE69424915T2 (de) 2001-01-18
SK282178B6 (sk) 2001-11-06
ES2147567T3 (es) 2000-09-16
NO943524L (no) 1995-03-23
EP0972517A2 (de) 2000-01-19
UA49787C2 (uk) 2002-10-15
EP0649658B1 (de) 2000-06-14
PT972517E (pt) 2004-11-30
AU7411794A (en) 1995-04-06
ATE193827T1 (de) 2000-06-15
NZ264502A (en) 1997-06-24
CA2132578A1 (en) 1995-03-23
GR3034360T3 (en) 2000-12-29
DK0972517T3 (da) 2004-11-08
SK114894A3 (en) 1995-11-08
RU94034104A (ru) 1996-11-10
EP0972517A3 (de) 2000-01-26
DE69424915D1 (de) 2000-07-20
DK0649658T3 (da) 2000-09-11
EP0972517B1 (de) 2004-07-07
EP0649658A1 (de) 1995-04-26
HU9402726D0 (en) 1994-12-28
CZ289742B6 (cs) 2002-03-13
DE69433889T2 (de) 2005-06-30
MY112405A (en) 2001-06-30
DE69433889D1 (de) 2004-08-12
CA2132578C (en) 1998-10-13
RU2148406C1 (ru) 2000-05-10
US6121263A (en) 2000-09-19
NZ299690A (en) 1997-11-24
HUT71119A (en) 1995-11-28
US5484612A (en) 1996-01-16
SG52568A1 (en) 1998-09-28
IL111025A0 (en) 1994-11-28
AU690132B2 (en) 1998-04-23
ES2224517T3 (es) 2005-03-01
NO943524D0 (no) 1994-09-22
KR100383402B1 (ko) 2003-09-22

Similar Documents

Publication Publication Date Title
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
NO852872L (no) Fremgangsmaate for fremstilling av nye tetrapyrroler.
IL98382A0 (en) Heterocyclene derivatives
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
NO910033L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-3-fenoksypropylaminoforbindelser.
GEP19991535B (en) Process for the Preparation of 7-Hydroxy Taxanes
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE68920022D1 (de) Indolessigsäure-derivate, verfahren zur herstellung sowie arzneimittel, die diese als aktive mittel enthalten.
ATE128354T1 (de) Verwendung von 7-oh-1,2-benzopyron zur herstellung eines arzneimittels zur behandlung von malignen tumoren beim menschen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0972517

Country of ref document: EP

REN Ceased due to non-payment of the annual fee